• Murat Akova, Ankara, Turkey
  • Maiken Arendrup, Copenhagen, Denmark
  • Sujata Bhavnani, Schenectady, NY, United States
  • Marco Cavaleri, London, United Kingdom
  • Herman Goossens, Edegem, Belgium
  • David Hooper, Boston, MA, United States
  • William Hope, Liverpool, United Kingdom
  • John Rex, Wellesley, MA, United States
  • Jesús Rodríguez Baño, Seville, Spain
  • Keith Rodvold, Chicago, IL, United States
  • Michael Sharland, London, United Kingdom
  • Judith Steenbergen, Boston, MA, United States
  • Sumathi Nambiar, Washington D.C., United States
Antimicrobial drug resistance remains a pressing public health problem. There has been a resurgence in interest in tackling AMR. This conference focusses on the development of new antimicrobial agents for AMR. It is a multidisciplinary meeting that involves basic scientists, clinical academics, regulatory bodies, funding bodies and the pharmaceutical industry. Its scope stretches from chemistry to clinical development, from neonates to adults, from bacteria to fungi – all with a global perspective. The meeting is practical, interactive with plenty of time for networking. We will happily accept original data for poster and platform presentations. We are also especially interested in supporting young investigators and researchers from low to middle income countries.

Drug development for AMR is a rapidly moving field. The stakes are high. A difficult riskbenefit balance must be struck. There are relatively few new classes of antibiotics and each requires highly skilled and experienced investigators to ensure these compounds reach patients. This meeting is the forum where those issues are discussed and debated.

Contact Person (Scientific Programme)

Administrative Secretariat

Venue Info

Event Map
Venue Details
Intercontinental Lisbon
R. Castilho 149, 1099-024 Lisbon
An exciting and engaging 4-day programme is planned, with a faculty of experts scheduled to present on a variety of topics relating to antimicrobial resistance, new drug development, and stewardship strategies.

Tuesday, 4 September 2018

08:30 - 09:30
Opening Talks and Welcome
09:30 - 10:00
Coffee Break
10:00 - 12:00
Bootcamp: Medicinal Chemistry
Chairperson(s): John Griffin
Chairperson(s): Heinz Moser
10:00 - 10:30
Drug-Likeness: Physicochemical Properties in Small-Molecule Drug Discovery
Speaker(s): Andrea Decker
10:30 - 11:00
Drug Discovery of Antibiotics: The Importance of Physicochemical Properties
Speaker(s): Heinz Moser
11:00 - 11:30
Emerging Artificial Intelligence Approaches in Drug Discovery and their Application to Antibiotic Design
Speaker(s): John Griffin
11:30 - 12:00
Roundtable Discussion
Speaker(s): Andrea Decker
Speaker(s): John Griffin
Speaker(s): Heinz Moser
Speaker(s): John H. Rex
12:00 - 13:00
Lunch and Poster Viewing
13:00 - 15:00
Bootcamp: Preclinical Toxicology
Chairperson(s): Ursula Theuretzbacher
13:00 - 13:30
Pitfalls in Preclinical Development from the Regulatory Perspective (FDA)
Speaker(s): Terry Miller
13:30 - 14:00
Making Safety a Part of Drug Design
Speaker(s): Claire Sadler
14:00 - 14:30
Real life story of unexpected toxicity - Lessons to learn
Speaker(s): Ryan Cirz
14:30 - 15:00
Roundtable discussion
Speaker(s): Ryan Cirz
Speaker(s): Terry Miller
Speaker(s): Claire Sadler
Speaker(s): Ursula Theuretzbacher
15:00 - 15:30
Coffee Break
15:30 - 17:00
Regulatory Roundtable
Chairperson(s): Marco Cavaleri
Chairperson(s): Sumathi Nambiar
Speaker(s): Edward Cox
Speaker(s): Junko Sato
Speaker(s): Ming Zhao
16:10 - 16:30
Coffee Break
17:00 - 17:15
Short Break
17:15 - 20:00
Wellcome-sponsored Cocktail Reception

Wednesday, 5 September 2018

08:30 - 11:00
State of the Art Lecture: New Antibacterial Agents
Chairperson(s): William Hope
Chairperson(s): Keith Rodvold
08:30 - 08:55
Speaker(s): Roger M. Echols
08:55 - 09:20
Relebactam + Imipenem/Cilastatin
Speaker(s): Amanda Paschke
09:20 - 09:45
Speaker(s): Larry Tsai
09:45 - 10:10
Speaker(s): Evan Tzanis
10:10 - 10:35
Speaker(s): David Huang
10:35 - 11:00
Speaker(s): Steven Gelone
11:00 - 11:30
Coffee Break
11:30 - 12:00
Young Investigator Lecture: Clinical trial design, clinical endpoints, recruitment issues for clinical trials in AMR
Chairperson(s): Sumathi Nambiar
Chairperson(s): Jesús Rodríguez-Baño
Speaker(s): Marlieke de Kraker
12:00 - 13:00
Lunch and Poster Viewing
13:30 - 14:30
Plenary: Preparing for the Black Swans of resistance
Chairperson(s): Murat Akova
Speaker(s): David Livermore
14:30 - 14:40
Short Break
14:40 - 16:10
Rapid Diagnostic Testing for AMR
Chairperson(s): Maiken Cavling Arendrup
Chairperson(s): Judith Steenbergen
14:40 - 15:10
Next Generation AST: Rapid Results and Expanded Antibiotic Menus
Speaker(s): Eric Stern
15:10 - 15:40
Streamlining antibacterial clinical development through the use of rapid diagnostics
Speaker(s): Andrew Tomaras
15:40 - 16:10
Clinical Applications: Implementation and clinical management
Speaker(s): Rosanna Peeling
16:10 - 16:30
Coffee Break
16:30 - 18:00
Pharmacodynamics of Adjunctive Therapies: Paradigm Changing Therapies
Chairperson(s): Sujata Bhavnani
Chairperson(s): Marco Cavaleri
16:30 - 16:48
Regulatory Perspectives
Speaker(s): Marco Cavaleri
16:48 - 17:06
Antibiotic Potentiators
Speaker(s): Troy Lister
17:06 - 17:24
Bacterial Growth Rate Modulators
Speaker(s): Paul Ambrose
17:24 - 17:42
Monoclonal Antibodies
Speaker(s): Rene L Russo
17:42 - 18:00
Phage Therapy
Speaker(s): Harald Brüssow

Thursday, 6 September 2018

08:30 - 10:30
Building the Evidence Base to Inform AMR-Related Decision-Making
Chairperson(s): John H. Rex
08:35 - 08:55
Policy overview: why is surveillance important and what do policy makers need?
Speaker(s): Jeremy Knox
08:55 - 09:15
The global policy/IACG perspective
Speaker(s): Haileyesus Getahun
09:15 - 09:35
Surveillance Landscape: overview of current programmes and initiatives
Speaker(s): Sharon Peacock
09:35 - 09:55
Surveillance in pharma: a case-study for data sharing.
Speaker(s): Barry Cookson
10:00 - 10:30
Roundtable Discussion
Speaker(s): Jeremy Knox
Speaker(s): Kevin Krause
Speaker(s): Seamus O'Brien
Speaker(s): Evelina Tacconelli
Speaker(s): Didem Torumkuney
10:30 - 11:00
Coffee Break
11:00 - 11:30
Young Investigator Lecture: Metallobetalactamases (Epidemiology, Drug Design, Diagnosis and Treatment)
Chairperson(s): David C. Hooper
Chairperson(s): David Livermore
Speaker(s): Sara Boyd
11:30 - 12:30
Plenary: Stewardship of New and Last-Resort Antibiotics in LIMCs - Balancing Access and Control?
Chairperson(s): David C. Hooper
Speaker(s): Marc Mendelson
12:30 - 14:00
Lunch and Poster Viewing
14:00 - 15:30
State of the Art Lecture: Antifungal agents and Antifungal Drug Development
Chairperson(s): Maiken Cavling Arendrup
Chairperson(s): Sumathi Nambiar
14:00 - 14:30
5 unmet medical needs for antifungal chemotherapy
Speaker(s): David W. Denning
14:30 - 15:00
Review of the antifungal pipeline
Speaker(s): John R. Perfect
15:00 - 15:30
Design and conduct of Phase II and III clinical trials for new antifungal agents
Speaker(s): Peter Pappas
15:30 - 16:00
Coffee Break
16:00 - 17:30
Approaches to Tackle AMR in Low-to-Middle Income Countries
Chairperson(s): Marc Mendelson
16:00 - 16:30
Challenges and barriers to optimal dosing of old drugs for the management of common bacterial infections in LMICs
Speaker(s): Alisdair MacGowan
16:30 - 17:00
What is the evidence base for combinations of old antibiotics for the treatment of MDR bacteria?
Speaker(s): Evelina Tacconelli
17:00 - 17:30
Do we need new financial models to secure supply of old antibiotics?
Speaker(s): Christine Årdal

Friday, 7 September 2018

08:30 - 10:00
Breakpoints for new Antimicrobial Agents
Chairperson(s): Maiken Cavling Arendrup
08:30 - 08:45
The role of breakpoint committees in the development of new antibacterial agents - EUCAST
Speaker(s): Christian Giske
08:45 - 09:00
The role of breakpoint committees in the development of new antibacterial agents - US perspective
Speaker(s): Jean Patel
09:00 - 09:15
The role of breakpoint committees in the development of new antifungal agents
Speaker(s): Shawn R. Lockhart
09:15 - 09:30
How to define wild type distributions of target organisms
Speaker(s): Maiken Cavling Arendrup
10:00 - 10:30
Coffee Break
10:30 - 11:00
Young Investigator Lecture: Pharmacokinetics/Pharmacodynamics
Chairperson(s): George Drusano
Chairperson(s): Alisdair MacGowan
Speaker(s): Nikolas Onufrak
11:00 - 12:00
Plenary: Days of Future Passed: What is Needed To Discover and Develop New Antimicrobials?
Chairperson(s): Murat Akova
Speaker(s): Michael Dudley
12:00 - 13:30
Lunch and Poster Viewing
13:30 - 15:00
Clinical Trial Design for AMR
Chairperson(s): Herman Goossens
Chairperson(s): Jesús Rodríguez-Baño
13:30 - 13:50
Adaptative trials with new antibiotics
Speaker(s): Cornelis H. Van Werkhoven
13:50 - 14:10
 Challenges for pathogen-target trials
Speaker(s): Jesús Rodríguez-Baño
14:10 - 14:30
Advanced observational studies for MDR pathogens: useful or confounding?
Speaker(s): Mical Paul
14:30 - 14:50
Challenges of trials with new antibiotics: the view of the industry
Speaker(s): John Tomayko
15:00 - 15:30
Coffee Break
15:30 - 17:00
Drug Discovery in Academia
Chairperson(s): David C. Hooper
15:30 - 16:00
Drugs from bugs of bugs – An unexpected source and collaboration
Speaker(s): David Andes
16:00 - 16:30
Discovering antibiotic adjuvants to extend the life of existing drugs
Speaker(s): Gerry D Wright
16:30 - 17:00
Overview of techniques used in drug discovery
Speaker(s): Ian Gilbert

There are several options to transfer from the Airport to the hotel

By taxi: 15-20 minutes, the cost is around €15-17.
By bus: (Aerobus) to Praça Marquês de Pombal, the nearest stop to the hotel then a 10 minute walk (uphill).
By metro: Aeroporto station until the end of red line (São Sebastião station), then a 10 minute walk.

The hotel can also arrange a private transfer with an English speaking driver : 

Car ( Mercedes E Class - space for 3 people and 3 bags) - Price : €50
Mini-van ( Mercedes V Class - space for 6 people and 6 bags) - Price : €80

Private transfers will have to be booked with the hotel directly ( + 351 213 818 700 )
Following the submissions of many strong abstracts, the Programme Committee members have selected a range to be displayed as posters, to be hanging in the venue throughout the conference. The posters are grouped into 7 categories, listed alphabetically below:
Category 1: Biofilm
Abstract Number Title
1 Potential of Marine Actinomycetes for the Reduction of Biofilm Formation
21 New insights into the effect of azithromycin on Pseudomonas aeruginosa attachment
47 Glutathione deactivates Pseudomonas aeruginosa virulence factor pyocyanin function, enhance antibiotic efficacy in killing biofilms and facilitate host cellular growth. 
65 Unravelling the antibiofilm mechanism of action of the viral-derived membrane-active peptide pepR
71 The Influence of Marine Bacteria-derived Biosurfactants on Staphylococcus aureus and Proteus mirabilis Biofilm Formation.
73 Eradication and phenotypic tolerance of Burkholderia cenocepacia biofilms exposed to atmospheric pressure non-thermal plasma
118 Screening of the selected properties of biofilm forming pathogenic bacteria isolated from horses
125 A study of antibiotic susceptibility and biofilm production of bacteria isolated from diabetic foot ulcer patients 
Category 2: Drug Discovery
Abstract Number Title
3 Synthesis characterization and biological activity of  lanthanide derivatives and their complexes with nalidixic acid against Escherichia coli and Staphylococcus aureus
23 Shotgun metagenomic and functional metagenomic approach for unraveling of antimicrobial potential of microbial communities from Western Balkans glacial lakes sediments
25 Analysis of Escherichia coli essential genes in 63 strains complete genomes, a search of new therapeutic alternatives.
28 “Receptor specificity and mode of action of SAHKI, an inhibitor of two component histidine kinase to attenuate infections caused by multiple drug resistant Staphylococcus aureus”
30 Phagemid-based expression of synthetic sRNA to silence shiga toxins; a strategy towards RNA-based therapeutics 
36 Genome wide profiling of Mycobacterium Tuberculosis exposed to novel anti-tuberculosis agent, thienothiazole carboxamide (TTCA) derivatives. 
37 Structure-activity relationships of TTCA series for identification of novel anti-tubercular agents 
38 Antibacterial and Synergistic Activity of Δ9-tetrahydrocannabinol.
39 In Quest of A Novel Scaffold To Combat MDR/XDR Tuberculosis
42 Miniaturization of whole-cell bacterial bioreporter assay to identify quorum-sensing interference activity of chemical compounds
43 In vitro Characterization of Novel P. aeruginosa Quorum Sensing Inhibitors identified by In Silico Screening
44 Targeting Quorum sensing: Discovery of LsrK inhibitors
53 Next-generation antimicrobials based on CRISPR-Cas3 enhanced bacteriophages.
55 High Density Transposon Mutant Profiling Enables the Discovery and Development of Novel Antimicrobials
59 Evaluating bacterial thermoregulation mechanisms as an alternative drug target
61 Modulation of Quorum Sensing in a Gram-Positive Pathogen by Linear Molecularly Imprinted Polymers with Anti-infective Properties.
62 Investigation of Narrow Spectrum Targets in Antibacterial Drug Discovery
70 Carbonyl Cyanide m-Chlorophenylhydrazone (CCCP) and no Other Efflux Pump Inhibitor Reversed Resistance to Polymyxins in Enterobacteriaceae Isolated from Bloodstream Infections
74 A New Endolysin from Acinetobater baumannii Ab105Ф1 bacteriophage with Gram-negative antimicrobial activity
75 Antimicrobial activity from mutant lytic phage obtained from the Ab105-2ϕ prophage harbouring clinical strain of Acinetobacter baumannii.
79 Nanotechnology: the future of antibiotic therapy 
91 Screening and Synergy Study Applications for New Antibacterial Compounds against ESKAPE bacteria
94 Mutational Landscape of TEM-1 beta-lactamase activity through allosteric Dynamic Coupling Analysis
97 New tricks for old drugs – Uncovering the mechanism of action of thioridazine in Salmonella Typhimurium
98 Repurposing zinc and cobalt organometallic compounds as effective antimicrobials against Gram-positive and -negative bacteria
112 A polypharmacological approach to address antibacterial resistance: inhibition of Histidine Kinases by targeting the ATP binding domain. 
114 Understanding the Bacterial Permeation of Drug-Like Molecules
130 Identification of drug and vaccine candidates based on functional annotation of hypothetical proteins in Neisseria gonorrhoeae.
134 Small-molecule anti-virulence agents F12 and F19 against Gram-positive pathogens
135 Synthesis and Evaluation of Novel Bacterial Topoisomerase Inhibitors with Reduced hERG Inhibition
137 Repurposing of a non-antimicrobial drug to treat bacterial infections caused by Gram-negative pathogens
142 Identification of potential narrow-spectrum antibiotics for the treatment of bacterial enteric infections through a phenotypic screening in Shigella flexneri
147 Discovery of FtsZ and FtsA Inhibitors 
148 Prediction of Novel Antimicrobials using Large Screening Data
L5 Antibiofilm activity of ocellatin peptides against multidrug-resistant Pseudomonas aeruginosa
Category 3: Drug Development
Abstract Number Title
15 Towards new β-lactamase inhibitors: chemistry and modeling driven approach
17 Octapeptins: New Lipopeptides for XDR Gram-Negative Infections
18 Glycopeptide derivatives with potent activity against multi-drug resistant pathogenic bacteria
31 BARDA’s Model to Support Antibiotic Development
33 Getting drug into Gram negative bacteria: exploiting the porins pathway
35 Potential antimicrobials fighting XDR-pathogens; A study on the isolation and characterization of lytic bacteriophages effective on colistin resistance K. pneumoniae
45 Fighting bacterial skin infections with tetraspanin-derived peptides
46 Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor 
49 The Safety of Iclaprim among Diabetic Patients for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Pooled REVIVE Studies 
50 Surveillance of Iclaprim Activity: In Vitro Susceptibility of Drug-Susceptible and -Resistant Beta-hemolytic Streptococci Collected During 2012-2016 from Skin and Skin Structure Infections
51 In vitro activities of omadacycline against rapidly growing mycobacteria 
52 Iclaprim Activity Against Clinical Isolates Causing Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Phase 3 REVIVE-1 and REVIVE-2 Studies
54 Building a European Laboratory Network for Anti-infective Clinical Trials – COMBACTE LAB-Net: 5 Years in
56 SMT-571: The Development of a Novel Oral Antibiotic to Treat Multi-Drug Resistant Neisseria gonorrhoeae
57 Characterization of novel cyclic polypeptides with potent in vitro and in vivo activity against multidrug-resistant Gram-negative pathogens, and with reduced nephrotoxicity relative to colistin
58 Pharmacokinetics and Efficacy of Ceftolozane/Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbit Model
60 Surveillance of Iclaprim Activity: In Vitro Susceptibility of Gram-Positive Skin and Skin Structure Pathogens Collected During 2004-2016
63 A phase 3, randomized, double-blind, multi-center study to compare the safety and efficacy of IV to oral omadacycline to moxifloxacin for the treatment of adult patients with CABP (The OPTIC Study)
64 A phase 3 randomized, double-blind, multi-center study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study)
68 Outer membrane protein targeting antibiotics (OMPTAs): In vitro and in vivo characterization of a novel class of compound
72 Project Pillar Phase II: Provision of Clinical Strains
80 In Vitro Activity Evaluation of a Next-Generation Polymyxin, SPR206, against Non-Fermentative Gram-Negative Bacilli Responsible for Human Infections
81 Activity of Investigational Polymyxin-B-like Compound (SPR206) Against Set of Enterobacteriaceae Organisms Responsible for Human Infections
84 Assessment of AUC-Based Therapeutic Drug Management (TDM) Algorithms for Plazomicin Therapy in Patients with Bloodstream Infection (BSI)
85 Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Plazomicin Dose Selection and Recommendations for Interpretive Criteria for In Vitro Susceptibility Testing for Enterobacteriaceae 
86 Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2 and 3 Studies
87 Targeting polymyxin- and carbapenem-resistant Klebsiella pneumoniae (KPC-KP) via a novel, integrated mechanistic approach
88 Comprehensive Penicillin-Binding Protein (PBP) Occupancy Patterns of 18 Drugs in Acinetobacter baumannii
93 A panel of MDR P. aeruginosa clinical isolates for pharmacology studies with murine lung and thigh infection models 
95 Lead Development of PolC Polymerase Inhibitors against Resistant Gram-positive Pathogens
96 Activity of Antimicrobial peptides against Mycobacterium abscessus
99 Lysin CF-301 (Exebacase) Resensitizes Methicillin-Resistant Staphylococcus aureus (MRSA) to Penicillin Derivatives and First Generation Cephalosporins 
100 Pharmacokinetics-Pharmacodynamics (PK-PD) of Plazomicin (PLZ) against Carbapenem-Resistant Enterobacteriaceae (CRE) in Neutropenic Murine Thigh Infection and Pneumonia Models
101 Method for Generating a Pharmacokinetic/Pharmacodynamic (PK/PD) Breakpoint from Murine Infection Studies with Multiple Strains.
103 A novel approach to decrease efflux-mediated drug resistance in Neisseria gonorrhoeae
104 High-dose Nitric Oxide inhibits growth of Mycobacterium Abscessus
107 The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States
110 Evaluation of Proline-rich antimicrobial Peptides for Treatment of Ventilator-Associated Pneumoniae
111 Tedizolid In Vitro Activity against a Contemporary Challenge Collection of Multidrug-Resistant Enterococcal Clinical Isolates
113 Novel inhibitors of leucyl-tRNA synthetase
115 Activity of Meropenem-Vaborbactam and Comparator Agents against Multidrug-Resistant Enterobacteriaceae Isolates from the United States Analyzed by Site of Infection
116 Analysis of Oritavancin In vitro Activity against Enterococcal Isolates and Resistant Subsets
117 Activity of Meropenem-Vaborbactam and Comparator Agents against Multidrug-Resistant Enterobacteriaceae Isolates from the Unites States Analyzed by Site of Infection
122 Nano-mupirocin for the treatment of resistant gonorrhea
131 Population Pharmacokinetic Analyses for Arbekacin After Administration of ME1100 Inhalation Solution
136 Importance of Utilizing Local Carbapenem-Resistant Enterobacteriaceae (CRE) Surveillance Isolates to Determine Potential Efficacy of Novel Agents: Meropenem/Vaborbactam (M/V) Exhibits Robust Activity at a US Healthcare Center with a Predominance of Non-KPC-Producing CRE
138 In Vivo Efficacy of SPR206 in an Immunocompetent Murine Ascending UTI Infection Model Caused by Escherichia coli  
139 In Vivo Efficacy of SPR206 in Murine Lung and Thigh Infection Models Caused by Multi-Drug Resistant Pathogens Pseudomonas aeruginosa and Acinetobacter baumannii 
143 In Vivo Efficacy of SPR206 in Murine Lung and Thigh Infection Models Caused by Multi-Drug Resistant Pathogens Pseudomonas aeruginosa and Acinetobacter baumannii
144 In Vivo Efficacy of SPR206 in an Immunocompetent Murine Ascending UTI Infection Model Caused by Escherichia coli 
145 Understanding the SAR Interplay for Kidney Exposure and Cytotoxicity Facilitates the Design of Improved Polymyxin Derivatives – Identification of SPR206 as a Development Candidate
146 A GLP 14-Day Repeat Dose Toxicology Study of SPR206 in Monkeys  
L1 Proteomics Analysis of Proteins Associated with Urinary Tract Infections
L2 Pharmacokinetics and Pharmacodynamics of Tebipenem (SPR859) for Multidrug Resistant Enterobacteriaceae in a Hollow Fibre Infection Model
L3 Pharmacokinetics and Pharmacodynamics of SPR994 for Multidrug Resistant Enterobacteriaceae
149 A Hollow-Fiber Infection Model  to Evaluate the Prevention of On-Therapy Resistance of Neisseria gonorrhoeae to Gepotidacin
Category 4: Epidemiology
Abstract Number Title
12 Molecilar epidemiology and drug susceptibility of Pseudomonas aeruginosa in a tertiary care centre in Kosovo
16 Antibiogram of Gram-negative human pathogens isolated in India. 
22 Multiple-Antibiotic Resistance and presence of CTX-M genes among Enterobacteriaceae isolates from different sources in Iwo, Osun State, Nigeria.
32 Drug resistant pattern of bacterial isolates in infected wounds at Bahir Dar Regional health research laboratory center, Northwest Ethiopia
34 Antimicrobial resistance, genomic and molecular epidemiologic analysis of Salmonella serovars in Hacettepe University Hospitals
48 A survey on multidrug resistance and virulence genes in Pseudomonas aeruginosa isolates in a major hospital in Shiraz, Iran
69 Study Of Extended Spectrum B-Lactamase Producing Enterobacteriacae From healthcare workers From Different Hospitals In Khartoum State 2016-2017
76 Isolation and Characterization of NDM-1 Producing Klebsiella Pneumoniae from three Palestinian Hospitals  
90 Species diversity of IMP-producing Acinetobacter isolated from patients in pediatric and neonatal intensive care units: clinical features, diagnosis and treatment.
92 Clavulante stability in widely used child-appropriate formulations is unlikely to be adequate for use in treating young children in Asia
123 Detection of CPE in rectal swaps using four different phenotypic techniques and Check-Direct CPE multiplex PCR, using PCR and sequencing as a reference methods.
124 Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa bacteremia in Southern Veterans Hospital 
127 Ciprofloxacin-Resistant Salmonella enterica serovar Typhi infections in Travelers returning from India, Republic of Korea
128 Genetic relationships among Fluoroquinolone-resistant Shigella sonnei isolates from humans in Republic of Korea, 2008-2016
129 Comparative analysis of extended-spectrum β-lactamase (ESBL) CTX-M-15-producing Salmonella enterica serovar Enteritidis isolates from human and chicken in Republic of Korea.
132 Complete genome sequence of a blaKPC-2-positive Klebsiella pneumoniae strain isolated from the effluent of an urban sewage treatment plant in Japan
140 Current oral (PO) regimen options are suboptimal for hospitalized patients with urinary tract infections (UTI) due to contemporary resistant Enterobacteriaceae (ENT): A multicenter analysis
141 The impact of antibiotic resistance on hospitalized patients with Enterobacteriaceae (ENT) urinary tract infections (UTI): A multicenter analysis
Category 5: Fungal Infections
Abstract Number Title
4 Development of Antifungal Biopharmaceutical Dectin1-Fc
27 Impact of Bacillus licheniformis SV1 derived glycolipid on Candida glabrata biofilm
78 Effect of new antifungal peptides resistant to action of MDR pumps on Candida cells
119 In vitro susceptibility of five Candida species to photodynamic therapy using curcumin as photosensitizer.
L4 Ibrexafungerp (formerly SCY-078) Displays Potent In Vitro Activity Against C. Glabrata Isolates with Mutations in fks Genes.
Category 6: Management of Resistance
Abstract Number Title
9 Study of ompk35 and ompk36 Expression in Carbapenem Resistant ESBL Producing Clinical Isolates of Klebsiella Pneumoniae
11 Modified Pattern of Acinetobacter baumannii After Acquisition of Colistin Resistance
19 Effect of amoxicillin metabolites on the induction of resistance to amoxicillin susceptible bacterial strains.
66 Effect of Efflux Pump Inhibitors to Efficacy of Meropenem on Acinetobacter spp. Clinical Isolates
67 Investigating the Effect of Phenylalanine-arginine-beta-naphthylamide to Minimum Inhibition Concentration of Ciprofloxacin and Expression of Efflux Pump Genes in Acinetobacter baumannii Clinical Isolates 
77  Improve Awareness and Understanding Antibiotics Resistant Through Participation in Public Cultural Forums
83 Optimizing Aminoglycoside Selection for KPC-Producing Klebsiella pneumoniae with Aminoglycoside Modifying Enzyme AAC(6’)-Ib
120  Evaluation and interpretation of antimicrobial resistance in patient's Rifampicin- or Multidrug-Resistant Tuberculosis by Northern Iran: An analysis of past 10 years
121 Are we striding towards pre antibiotic Era? Identification of Escherichia coli harbouring novel variant  of New Delhi metallo beta lactamaes (NDM-11)  along with  colistin resistance gene mcr-1.
133 Growth Inhibition of Streptococcaceae in Healthy Gut Flora by Interocin of Streptococcus intermedius TYG1620 Isolated from a Human Brain Abscess
Category 7: Plants
Abstract Number Title
8 Antibacterial Potentials of the Leaf Extracts of Siam Weed (Chromolaena odorata) on Wound Isolates
13 Innate Defense Regulators (IDRs) – Agnostic Therapy to Treat Bacterial Infections and Fight Resistance.
40 Growth and biofilm formation inhibition activity against carbapenem resistant Acinetobacter baumannii is obtained reproducibly from 7 different water extracts of complex mixes of edible plants
89 Antibacterial and antioxidant activity of ethanolic extracts of Uvaria chamae roots on Bacteria Multiresistance: Involvement of chalcones and dihydrochalcones
105 Valuation of some plants of the traditional Beninese pharmacopoeia used in the control of pathogenic enterobacteria
108 Antimicrobial Activities of Thymus vulgaris and Cymbopogon citratus on
If you are an ASM member, please kindly send the membership proof to lisbon2018@escmid.org in order to be given the membership discount.
Cancellation Policy (Terms and Conditions): Over 30 days before the start of the course - 60% of the amount will be charged. Less than 30 days before the start of the course - 100% of the amount will be charged. No charges apply for a suitable, qualified substitute participant. The organizers reserve the right to cancel the course up to two weeks before the start date. A full refund of the course fees will be allowed, but the organizers cannot be held responsible for any other costs incurred (transports, hotels, etc.).
The ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial
Resistance, Lisbon, Portugal, 04/09/2018-07/09/2018 has been accredited by the European
Accreditation Council for Continuing Medical Education (EACCME®) with 24 European CME credits
(ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent
in the educational activity.
Please find the full accreditation document here.